Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 18.03.2019 1 Acta Cytol 2 Ann Oncol 1 Ann Surg Oncol 3 Anticancer Res 9 BMC Cancer 2 Breast Cancer 4 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 8 Breast Cancer Res Treat 2 Cancer 1 Cancer Lett 2 Cancer Res 4 Clin Breast Cancer 3 Clin Cancer Res 1 Curr Treat Options Oncol 1 Genes Chromosomes Cancer 4 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Oncol 2 J Nucl Med 4 N Engl J Med 2 Nature 1 Oncogene 2 Oncol Rep 2 PLoS Comput Biol 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Acta Cytol

1. KAPILA K, Alath P, Hebbar GH, Jaragh M, et al
   Correlation of Ultrasound Findings and Fine-Needle Aspiration Cytology for the Diagnosis of Axillary Lymph Node Metastasis in Patients with Breast Carcinoma.
   Acta Cytol. 2019;63:17-22.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
   BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
   Ann Oncol. 2019 Mar 12. pii: 5376517. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
3. HREBIEN S, Citi V, Garcia-Murillas I, Cutts R, et al
   Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.
   Ann Oncol. 2019 Mar 12. pii: 5376514. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

4. KANDAGATLA P, Shah NM, Jeruss JS
   ASO Author Reflections: Challenges in the Management of Young Women with Breast Cancer-Fertility Preservation and Pregnancy.
   Ann Surg Oncol. 2019 Mar 11. pii: 10.1245/s10434-019-07285.
   PubMed     Text format    
   
   

   
   Anticancer Res

5. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
   ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
   Anticancer Res. 2019;39:1267-1273.
   PubMed     Text format     Abstract available
   
   
6. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
   Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
   Anticancer Res. 2019;39:1343-1346.
   PubMed     Text format     Abstract available
   
   
7. PAPAIOANNOU E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, et al
   A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
   Anticancer Res. 2019;39:1217-1232.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. KUMAR N, Zhao D, Bhaumik D, Sethi A, et al
   Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
   BMC Cancer. 2019;19:215.
   PubMed     Text format     Abstract available
   
   
9. AL-QASSAB Y, Grassilli S, Brugnoli F, Vezzali F, et al
   Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
   BMC Cancer. 2018;18:1194.
   PubMed     Text format     Abstract available
   
   
10. XU Y, Kong S, Cheung WY, Bouchard-Fortier A, et al
    Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data.
    BMC Cancer. 2019;19:210.
    PubMed     Text format     Abstract available
    
    
11. CHEN Q, Liu Y, Zhu XL, Feng F, et al
    Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
    BMC Cancer. 2019;19:211.
    PubMed     Text format     Abstract available
    
    
12. CHAI D, Li K, Du H, Yang S, et al
    beta2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().
    BMC Cancer. 2019;19:223.
    PubMed     Text format     Abstract available
    
    
13. DE ALMEIDA BP, Apolonio JD, Binnie A, Castelo-Branco P, et al
    Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
    BMC Cancer. 2019;19:219.
    PubMed     Text format     Abstract available
    
    
14. RAMIREZ AB, Bhat R, Sahay D, De Angelis C, et al
    Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    BMC Cancer. 2019;19:220.
    PubMed     Text format     Abstract available
    
    
15. PHUNG MT, Tin Tin S, Elwood JM
    Prognostic models for breast cancer: a systematic review.
    BMC Cancer. 2019;19:230.
    PubMed     Text format     Abstract available
    
    
16. YADAV S, Hartkop S, Cardenas PY, Ladkany R, et al
    Utilization of a breast cancer risk assessment tool by internal medicine residents in a primary care clinic: impact of an educational program.
    BMC Cancer. 2019;19:228.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

17. MENESES-SANCHEZ P, Garcia-Hernandez SC, Porchia LM, Perez-Fuentes R, et al
    C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis.
    Breast Cancer. 2019 Mar 15. pii: 10.1007/s12282-019-00961.
    PubMed     Text format     Abstract available
    
    
18. FUKUI K, Masumoto N, Shiroma N, Kanou A, et al
    Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer. 2019 Mar 13. pii: 10.1007/s12282-019-00958.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

19. OZDEMIR BZ, Goodin JB, Bodenner DL
    Breast cancer prevention in older women: an algorithm to choose an optimal preventive agent.
    Breast Cancer (Dove Med Press). 2019;11:81-86.
    PubMed     Text format     Abstract available
    
    
20. CRONE M, Hallman K, Lloyd V, Szmyd M, et al
    The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.
    Breast Cancer (Dove Med Press). 2019;11:99-110.
    PubMed     Text format     Abstract available
    
    
21. GRECO SJ
    Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment.
    Breast Cancer (Dove Med Press). 2019;11:111-113.
    PubMed     Text format    
    
    
22. TREMMEL E, Hofmann S, Kuhn C, Heidegger H, et al
    Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration.
    Breast Cancer (Dove Med Press). 2019;11:87-97.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

23. FORTNER RT, Sisti J, Chai B, Collins LC, et al
    Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.
    Breast Cancer Res. 2019;21:40.
    PubMed     Text format     Abstract available
    
    
24. ECKER BL, Lee JY, Sterner CJ, Solomon AC, et al
    Impact of obesity on breast cancer recurrence and minimal residual disease.
    Breast Cancer Res. 2019;21:41.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

25. LYNCE F, Barac A, Geng X, Dang C, et al
    Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05191.
    PubMed     Text format     Abstract available
    
    
26. TIAN J, Chen X, Fu S, Zhang R, et al
    Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05183.
    PubMed     Text format     Abstract available
    
    
27. DE GROOT AF, Blok EJ, Charehbili A, Engels CC, et al
    Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05195.
    PubMed     Text format     Abstract available
    
    
28. CHRISCHILLES EA, Riley D, Letuchy E, Koehler L, et al
    Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05184.
    PubMed     Text format     Abstract available
    
    
29. MARSCHNER N, Trarbach T, Rauh J, Meyer D, et al
    Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05197.
    PubMed     Text format     Abstract available
    
    
30. FASCHING PA, Gass P, Haberle L, Volz B, et al
    Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05198.
    PubMed     Text format     Abstract available
    
    
31. YU C, Qin N, Pu Z, Song C, et al
    Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05177.
    PubMed     Text format     Abstract available
    
    
32. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
    Breast Cancer Res Treat. 2019 Mar 14. pii: 10.1007/s10549-019-05200.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

33. 
    "Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y.
    Cancer. 2019;125:1200.
    PubMed     Text format     Abstract available
    
    
34. PRINTZ C
    Circulating tumor cell count could be used to determine treatment of metastatic breast cancer.
    Cancer. 2019;125:1021.
    PubMed     Text format    
    
    

    
    Cancer Lett

35. TANG X, Tu G, Yang G, Wang X, et al
    Autocrine TGF-beta1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation.
    Cancer Lett. 2019 Mar 6. pii: S0304-3835(19)30130.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

36. BIRGE RB, Kasikara C, Davra V, Calianese D, et al
    Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer.
    Cancer Res. 2019 Mar 15. pii: 0008-5472.CAN-18-2614.
    PubMed     Text format     Abstract available
    
    
37. MADAK-ERDOGAN Z, Band S, Zhao YC, Smith BP, et al
    Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2849.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

38. MEYER C, Millan P, Gonzalez V, Spera G, et al
    Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy.
    Clin Breast Cancer. 2019 Jan 23. pii: S1526-8209(18)30713.
    PubMed     Text format     Abstract available
    
    
39. GIULIANI J, Bonetti A
    Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.
    Clin Breast Cancer. 2019 Feb 16. pii: S1526-8209(18)30803.
    PubMed     Text format     Abstract available
    
    
40. O'BRIEN GL, O'Mahony C, Cooke K, Kinneally A, et al
    Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    Clin Breast Cancer. 2019 Feb 6. pii: S1526-8209(18)30526.
    PubMed     Text format     Abstract available
    
    
41. HENDERSON J, Adams P, Barber K
    Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.
    Clin Breast Cancer. 2019 Feb 7. pii: S1526-8209(18)30542.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

42. KETTNER NM, Vijayaraghavan S, Durak MG, Bui T, et al
    Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer.
    Clin Cancer Res. 2019 Mar 13. pii: 1078-0432.CCR-18-3274.
    PubMed     Text format     Abstract available
    
    
43. ROTHE F, Silva MJ, Venet D, Campbell C, et al
    Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial.
    Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-2521.
    PubMed     Text format     Abstract available
    
    
44. SJOBERG E, Meyrath M, Milde L, Herrera M, et al
    A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer.
    Clin Cancer Res. 2019 Mar 8. pii: 1078-0432.CCR-18-1294.
    PubMed     Text format     Abstract available
    
    

    
    Curr Treat Options Oncol

45. GOLDVASER H, Amir E
    Role of Bisphosphonates in Breast Cancer Therapy.
    Curr Treat Options Oncol. 2019;20:26.
    PubMed     Text format     Abstract available
    
    

    
    Genes Chromosomes Cancer

46. FRITZ AJ, Gillis NE, Gerrard DL, Rodriguez PD, et al
    Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.
    Genes Chromosomes Cancer. 2019 Mar 15. doi: 10.1002/gcc.22731.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

47. COUSSY F, de Koning L, Lavigne M, Bernard V, et al
    A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32266.
    PubMed     Text format     Abstract available
    
    
48. ARROYO-CRESPO JJ, Arminan A, Charbonnier D, Deladriere C, et al
    Characterization of Triple-Negative Breast Cancer Preclinical Models Provides Functional Evidence of Metastatic Progression.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32270.
    PubMed     Text format     Abstract available
    
    
49. LI Z, Wang K, Shi Y, Zhang X, et al
    Incidence of second primary malignancy after breast cancer and related risk factors-is breast conserving surgery safe? A nested case-control study.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32259.
    PubMed     Text format     Abstract available
    
    
50. AMADOU A, Praud D, Coudon T, Danjou AMN, et al
    Chronic long-term exposure to cadmium air pollution and breast cancer risk in the French E3N cohort.
    Int J Cancer. 2019 Mar 9. doi: 10.1002/ijc.32257.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

51. ZHOU X, Li T, Chen Y, Zhang N, et al
    Mesenchymal stem cellderived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway.
    Int J Oncol. 2019 Mar 13. doi: 10.3892/ijo.2019.4747.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

52. CHRISTOPHERSON KM, Lei X, Barcenas CH, Buchholz TA, et al
    Outcomes of curative-intent treatment for breast cancer patients presenting with sternal or mediastinal involvement.
    Int J Radiat Oncol Biol Phys. 2019 Mar 6. pii: S0360-3016(19)30305.
    PubMed     Text format     Abstract available
    
    

    
    J Biol Chem

53. BRAGANZA A, Quesnelle K, Bickta J, Reyes C, et al
    Myoglobin induces mitochondrial fusion thereby inhibiting breast cancer cell proliferation.
    J Biol Chem. 2019 Mar 14. pii: RA118.006673. doi: 10.1074/jbc.RA118.006673.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

54. FREEDMAN RA, Gelman RS, Anders CK, Melisko ME, et al
    TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    J Clin Oncol. 2019 Mar 12:JCO1801511. doi: 10.1200/JCO.18.01511.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

55. KUMAR M, Salem K, Michel CJ, Jeffery JJ, et al
    (18)F-Fluoroestradiol Positron Emission Tomography Imaging of Activating Estrogen Receptor Alpha Mutations in Breast Cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224667. doi: 10.2967/jnumed.118.224667.
    PubMed     Text format     Abstract available
    
    
56. AZAD G, Siddique M, Taylor B, Green A, et al
    Reply to: Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Mar 8. pii: jnumed.119.226555. doi: 10.2967/jnumed.119.226555.
    PubMed     Text format    
    
    

    
    N Engl J Med

57. SCHMID P, Chui SY, Emens LA
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2019;380:987-988.
    PubMed     Text format    
    
    
58. AKTAS BY, Taban H, Aksoy S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:985-986.
    PubMed     Text format    
    
    
59. ALTUNDAG K
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986-987.
    PubMed     Text format    
    
    
60. O'SULLIVAN H, Collins D, O'Reilly S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986.
    PubMed     Text format    
    
    

    
    Nature

61. RUEDA OM, Sammut SJ, Seoane JA, Chin SF, et al
    Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
    Nature. 2019 Mar 13. pii: 10.1038/s41586-019-1007.
    PubMed     Text format     Abstract available
    
    
62. OBRADOVIC MMS, Hamelin B, Manevski N, Couto JP, et al
    Glucocorticoids promote breast cancer metastasis.
    Nature. 2019 Mar 13. pii: 10.1038/s41586-019-1019.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

63. KARADEDOU CT, Gomes AR, Chen J, Petkovic M, et al
    Correction: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
    Oncogene. 2019 Mar 13. pii: 10.1038/s41388-019-0770.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

64. ZHANG M, Liu Q, Li L, Ning J, et al
    Cytoplasmic MCSF facilitates apoptosis resistance by inhibiting the HIF1alpha/BNIP3/Bax signalling pathway in MCF7 cells.
    Oncol Rep. 2019;41:1807-1816.
    PubMed     Text format     Abstract available
    
    
65. XIE Q, Wang S, Zhao Y, Zhang Z, et al
    MicroRNA-216a suppresses the proliferation and migration of human breast cancer cells via the Wnt/beta-catenin signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7050.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Comput Biol

66. ALLAHYAR A, Ubels J, de Ridder J
    A data-driven interactome of synergistic genes improves network-based cancer outcome prediction.
    PLoS Comput Biol. 2019;15:e1006657.
    PubMed     Text format     Abstract available
    
    
67. CHAPMAN MP, Risom T, Aswani AJ, Langer EM, et al
    Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer.
    PLoS Comput Biol. 2019;15:e1006840.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

68. EGELAND NG, Austdal M, van Diermen-Hidle B, Rewcastle E, et al
    Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients.
    PLoS One. 2019;14:e0212527.
    PubMed     Text format     Abstract available
    
    
69. PIOTRZKOWSKA-WROBLEWSKA H, Dobruch-Sobczak K, Klimonda Z, Karwat P, et al
    Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
    PLoS One. 2019;14:e0213749.
    PubMed     Text format     Abstract available
    
    
70. ROEHRER S, Stork V, Ludwig C, Minceva M, et al
    Analyzing bioactive effects of the minor hop compound xanthohumol C on human breast cancer cells using quantitative proteomics.
    PLoS One. 2019;14:e0213469.
    PubMed     Text format     Abstract available
    
    
71. OW SGW, Ong PY, Lee SC
    Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
    PLoS One. 2019;14:e0213746.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

72. KOBOLD S
    Innate and adaptive immunity combined for cancer treatment.
    Proc Natl Acad Sci U S A. 2019;116:1087-1088.
    PubMed     Text format    
    
    

    
    Radiology

73. KIM JY, Kim JJ, Hwangbo L, Kang T, et al
    Diffusion-weighted Imaging of Invasive Breast Cancer: Relationship to Distant Metastasis-free Survival.
    Radiology. 2019 Mar 12:181706. doi: 10.1148/radiol.2019181706.
    PubMed     Text format     Abstract available
    
    
74. TAOUREL P
    Diffusion-weighted MRI for Breast Cancer: Why and with What Impact?
    Radiology. 2019 Mar 12:190331. doi: 10.1148/radiol.2019190331.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: